{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:13:37Z","timestamp":1790363617540,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"DOI":"10.7759\/cureus.56237","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T18:55:07Z","timestamp":1710528907000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Extranodal Natural Killer\/T-cell Lymphoma, Nasal Type Associated With Hemophagocytic Lymphohistiocytosis in a Patient With Recurrent Sinusitis"],"prefix":"10.7759","author":[{"given":"Bryce R","family":"Christensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-ting J","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.127","article-title":"Hemophagocytic lymphohistiocytosis (HLH) and related disorders","author":"Filipovich AH","year":"2009","unstructured":"Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009, 127-31. 10.1182\/asheducation-2009.1.127","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang K","year":"2011","unstructured":"Zhang K, Jordan MB, Marsh RA, et al.. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011, 118:5794-8. 10.1182\/blood-2011-07-370148","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan MB","year":"2019","unstructured":"Jordan MB, Allen CE, Greenberg J, et al.. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019, 66:e27929. 10.1002\/pbc.27929","journal-title":"Pediatr Blood Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4935","article-title":"A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis","volume":"105","author":"Voskoboinik I","year":"2005","unstructured":"Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood. 2005, 105:4700-6. 10.1182\/blood-2004-12-4935","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1086\/318796","article-title":"Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis","volume":"68","author":"G\u00f6ransdotter Ericson K","year":"2001","unstructured":"G\u00f6ransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, et al.. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet. 2001, 68:590-7. 10.1086\/318796","journal-title":"Am J Hum Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.11.014","article-title":"Histiocytic disorders: recent insights into pathophysiology and practical guidelines","volume":"16","author":"Filipovich A","year":"2010","unstructured":"Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010, 16:S82-9. 10.1016\/j.bbmt.2009.11.014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.04.034","article-title":"Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients","volume":"127","author":"Rivi\u00e8re S","year":"2014","unstructured":"Rivi\u00e8re S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, Fardet L. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014, 127:1118-25. 10.1016\/j.amjmed.2014.04.034","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten E","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M, et al.. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017, 130:2728-38. 10.1182\/blood-2017-06-788349","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter JI","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al.. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-31. 10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan MB","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011, 118:4041-52. 10.1182\/blood-2011-03-278127","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-814244","article-title":"Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis","volume":"132","author":"Chinn IK","year":"2018","unstructured":"Chinn IK, Eckstein OS, Peckham-Gregory EC, et al.. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018, 132:89-100. 10.1182\/blood-2017-11-814244","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1878-y","article-title":"IP-10\/CXCL10 and MIG\/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome","volume":"93","author":"Maruoka H","year":"2014","unstructured":"Maruoka H, Inoue D, Takiuchi Y, et al.. IP-10\/CXCL10 and MIG\/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014, 93:393-401. 10.1007\/s00277-013-1878-y","journal-title":"Ann Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli F","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, et al.. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020, 382:1811-22. 10.1056\/NEJMoa1911326","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-356261","article-title":"Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol","volume":"118","author":"Trottestam H","year":"2011","unstructured":"Trottestam H, Horne A, Aric\u00f2 M, et al.. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011, 118:4577-84. 10.1182\/blood-2011-06-356261","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S46255","article-title":"Hemophagocytic lymphohistiocytosis: review of etiologies and management","volume":"5","author":"George MR","year":"2014","unstructured":"George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014, 5:69-86. 10.2147\/JBM.S46255","journal-title":"J Blood Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter JI","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Aric\u00f2 M, et al.. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002, 100:2367-73. 10.1182\/blood-2002-01-0172","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5045\/br.2021.2020323","article-title":"Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults","volume":"56","author":"Kim YR","year":"2021","unstructured":"Kim YR, Kim DY. Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults. Blood Res. 2021, 56:S17-25. 10.5045\/br.2021.2020323","journal-title":"Blood Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au WY","year":"2009","unstructured":"Au WY, Weisenburger DD, Intragumtornchai T, et al.. Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009, 113:3931-7. 10.1182\/blood-2008-10-185256","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-160023","article-title":"Survival of patients with extranodal NK-cell lymphoma in the United States","volume":"140","author":"Xavier AC","year":"2022","unstructured":"Xavier AC, El-Mallawany NK, Ehrhardt MJ, Costa LJ, Cairo MS. Survival of patients with extranodal NK-cell lymphoma in the United States. Blood. 2022, 140:6563-4. 10.1182\/BLOOD-2022-160023","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00719","article-title":"Management of NK\/T-cell lymphoma, nasal type","volume":"15","author":"Allen PB","year":"2019","unstructured":"Allen PB, Lechowicz MJ. Management of NK\/T-cell lymphoma, nasal type. J Oncol Pract. 2019, 15:513-20. 10.1200\/JOP.18.00719","journal-title":"J Oncol Pract"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354142","article-title":"Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type","volume":"118","author":"Suzuki R","year":"2011","unstructured":"Suzuki R, Yamaguchi M, Izutsu K, et al.. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2011, 118:6018-22. 10.1182\/blood-2011-05-354142","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-672030","article-title":"The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases","volume":"127","author":"Kanakry JA","year":"2016","unstructured":"Kanakry JA, Hegde AM, Durand CM, Massie AB, Greer AE, Ambinder RF, Valsamakis A. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016, 127:2007-17. 10.1182\/blood-2015-09-672030","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim SJ","year":"2016","unstructured":"Kim SJ, Yoon DH, Jaccard A, et al.. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016, 17:389-400. 10.1016\/S1470-2045(15)00533-1","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2336-9","article-title":"Treatment outcome of patients with advanced stage natural killer\/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy","volume":"94","author":"Bi XW","year":"2015","unstructured":"Bi XW, Jiang WQ, Zhang WW, et al.. Treatment outcome of patients with advanced stage natural killer\/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. Ann Hematol. 2015, 94:1175-84. 10.1007\/s00277-015-2336-9","journal-title":"Ann Hematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2171-4","article-title":"Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer\/T-cell lymphoma patients","volume":"94","author":"Kim SJ","year":"2015","unstructured":"Kim SJ, Park S, Kang ES, Choi JY, Lim DH, Ko YH, Kim WS. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer\/T-cell lymphoma patients. Ann Hematol. 2015, 94:71-8. 10.1007\/s00277-014-2171-4","journal-title":"Ann Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951201)76:11<2351::aid-cncr2820761125>3.0.co;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi M","year":"1995","unstructured":"Yamaguchi M, Kita K, Miwa H, et al.. Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995, 76:2351-6. 10.1002\/1097-0142(19951201)76:11&lt;2351::aid-cncr2820761125&gt;3.0.co;2-1","journal-title":"Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0153","article-title":"DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China","volume":"22","author":"Li X","year":"2016","unstructured":"Li X, Cui Y, Sun Z, et al.. DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016, 22:5223-8. 10.1158\/1078-0432.CCR-16-0153","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi M","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, et al.. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011, 29:4410-6. 10.1200\/JCO.2011.35.6287","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li YX","year":"2006","unstructured":"Li YX, Yao B, Jin J, et al.. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol. 2006, 24:181-9. 10.1200\/JCO.2005.03.2573","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang Y","year":"2015","unstructured":"Yang Y, Zhu Y, Cao JZ, et al.. Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study. Blood. 2015, 126:1424-32. 10.1182\/blood-2015-04-639336","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811864","article-title":"Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population","volume":"61","author":"Ghione P","year":"2020","unstructured":"Ghione P, Qi S, Imber BS, et al.. Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. Leuk Lymphoma. 2020, 61:3331-41. 10.1080\/10428194.2020.1811864","journal-title":"Leuk Lymphoma"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee J","year":"2008","unstructured":"Lee J, Au WY, Park MJ, et al.. Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008, 14:1356-64. 10.1016\/j.bbmt.2008.09.014","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1037764","article-title":"High-dose therapy and autologous stem cell transplantation for extra-nodal NK\/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation","volume":"56","author":"Fox CP","year":"2015","unstructured":"Fox CP, Boumendil A, Schmitz N, et al.. High-dose therapy and autologous stem cell transplantation for extra-nodal NK\/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015, 56:3295-300. 10.3109\/10428194.2015.1037764","journal-title":"Leuk Lymphoma"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi M","year":"2018","unstructured":"Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type. Blood. 2018, 131:2528-40. 10.1182\/blood-2017-12-791418","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/226628-a-rare-case-of-extranodal-natural-killert-cell-lymphoma-nasal-type-associated-with-hemophagocytic-lymphohistiocytosis-in-a-patient-with-recurrent-sinusitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T18:55:11Z","timestamp":1710528911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/226628-a-rare-case-of-extranodal-natural-killert-cell-lymphoma-nasal-type-associated-with-hemophagocytic-lymphohistiocytosis-in-a-patient-with-recurrent-sinusitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.56237","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}